within Pharmacolibrary.Drugs.ATC.V;

model V08DA01
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.003,
    adminDuration  = 600,
    adminMass      = 3 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0035,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>V08DA01</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Perflutren, human albumin microspheres (marketed as Optison), is an injectable ultrasound contrast agent consisting of perflutren gas within human albumin microspheres. Its main use is to enhance echocardiographic imaging by creating better contrast in the blood pool. It is approved for clinical use for contrast enhancement in patients with suboptimal echocardiograms.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers receiving a single intravenous injection.</p><h4>References</h4><ol><li><p>Yang, L, et al., &amp; Yang, L (2006). [Sampling of exhaled gas after intravenous administration of octafluoropropane-containing human albumin micropheres in dogs]. <i>Nan fang yi ke da xue xue bao = Journal of Southern Medical University</i> 26(12) 1706–1708. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17259102/&quot;>https://pubmed.ncbi.nlm.nih.gov/17259102</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end V08DA01;
